4.5 Review

An outlook on using serial femtosecond crystallography in drug discovery

期刊

EXPERT OPINION ON DRUG DISCOVERY
卷 14, 期 9, 页码 933-945

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1080/17460441.2019.1626822

关键词

X-ray Free Electron Laser (XFEL); Serial Femtosecond Crystallography (SFX); structure based drug discovery (SBDD); membrane protein; Lipidic Cubic Phase (LCP); G Protein Coupled Receptor (GPCR)

资金

  1. Russian Foundation for Basic Research (RFBR) [18-02-40020, 18-54-00030]
  2. National Institutes of Health/National Institute of General Medical Sciences (NIH/NIGMS) [R35 GM127086]

向作者/读者索取更多资源

Introduction: X-ray crystallography has made important contributions to modern drug development but its application to many important drug targets has been extremely challenging. The recent emergence of X-ray free electron lasers (XFELs) and advancements in serial femtosecond crystallography (SFX) have offered new opportunities to overcome limitations of traditional crystallography to accelerate the structure-based drug discovery (SBDD) process. Areas covered: In this review, the authors describe the general principles of X-ray generation and the main properties of XFEL beams, outline details of SFX data collection and processing, and summarize the progress in the development of associated instrumentation for sample delivery and X-ray detection. An overview of the SFX applications to various important drug targets such as membrane proteins is also provided. Expert opinion: While SFX has already made clear advancements toward the understanding of the structure and dynamics of several major drug targets, its robust application in SBDD still needs further developments of new high-throughput techniques for sample production, automation of crystal delivery and data collection, as well as for processing and storage of large amounts of data. The expansion of the available XFEL beamtime is a key to the success of SFX in SBDD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据